Luminal Breast Cancer

Luminal breast cancer, also known as hormone receptor–positive breast cancer, is the most common subtype of breast cancer, accounting for more than 75% of all cases.

This subtype is characterized by the presence of female hormone receptors on cancer cells, which directly influences treatment strategies and prognosis.

What Is Luminal Breast Cancer?

Luminal breast cancer refers to breast cancer in which tumor cells express: Estrogen receptors (ER-positive) and/or Progesterone receptors (PR-positive) Female hormones play a key role in stimulating the growth of these cancer cells.

Main Subtypes of Luminal Breast Cancer

Luminal A
Key features

Strong ER/PR positivity
HER2 negative

Low cell proliferation (low Ki-67)

This subtype has the best prognosis
and responds very well to hormonal therapy

Luminal B

Key features

ER positive with higher cell proliferation
May be HER2 negative or HER2 positive
More aggressive than Luminal A

Treatment may include

Hormonal therapy
Chemotherapy:
Targeted therapy (in HER2-positive cases)

Why Is Luminal Breast Cancer So Common?

Because the breasts are organs that respond directly to female hormones, hormonal changes throughout life, such as menstruation, pregnancy, menopause, and the use of certain hormones, are all associated with the development of this type of cancer.

Treatment for luminol breast cancer is based on the patient's overall health condition, subtype (Luminal A or B), age, and overall health.

Treatment of Luminal Breast Cancer

1. Surgery

Breast-conserving surgery
Mastectomy, depending on clinical indications

2. Hormonal Therapy

Key Treatment

Tamoxifen
Aromatase inhibitors

Hormonal therapy significantly reduces the risk of recurrence.

3. Chemotherapy

Used in

High-risk disease
Lymph node involvement

4. Targeted Therapy

In the case of HER2-positive Luminal B breast cancer
The prognosis for luminal B breast cancer
Overall, it is considered a treatable breast cancer with a high survival rate. Many patients can live near-normal lives.

Especially if detected early and treated completely, including taking hormone medication as prescribed.

Important Points for Patients

Recurrence can occur late (5–10 years)
Long-term follow-up and medication adherence are crucial
Hormonal therapy should not be stopped without medical advice

summarize

Luminal breast cancer is the most common and one of the most treatable breast cancer subtypes. With appropriate therapy, patients have a strong chance of long-term disease control and good quality of life.

Understanding the cancer subtype is the first step toward choosing the most effective treatment.